Helena Lucia Barroso dos Reis , João Victor Jacomele Caldas , Carolina Azevedo Feltz , Danielle de Oliveira Machado , Lucas Donateli Rosa , Marize de Freitas Santos Neves , Dennis de Carvalho Ferreira , Antônio Chambo Filho , Neide Aparecida Tosato Boldrini
Giant condylomata acuminata, also known as Buschke-Lowenstein tumor is a rare form of tumor of the anogenital condylomata acuminata, which is a sexually transmitted infection (STI) caused by the human papillomavirus (HPV).
To report a case of giant condylomata acuminata in an immunocompetent patient.
The patient was referred to the Outpatient Clinic for Sexually Transmitted Infections and AIDS at a public hospital in the city of Vitória, Espírito Santo State, Brazil, reporting the onset of progressive growth verrucous lesions on the external genitalia for four months. The patient underwent surgical ablation, and giant condylomata diagnostic confirmation was obtained through histopathology. She was treated with 5% imiquimod cream in routine applications for eight consecutive weeks to avoid recurrence and was also vaccinated for HPV after the procedure.
Surgery excision is the treatment of choice in extensive genital condylomata lesions to exclude malignancy. Imiquimod use as adjuvant therapy for reducing recurrence seems to be adequate.
O condiloma acuminado gigante, também conhecido tumor de Buschke-Lowenstein, é uma apresentação rara do condiloma acuminado anogenital, que é uma infecção sexualmente transmissível (IST) causada pelo papilomavírus humano (HPV).
Relatar um caso de condiloma acuminado gigante em uma paciente imunocompetente.
A paciente foi encaminhada para o ambulatório de infecções sexualmente transmissíveis e AIDS de um hospital público na cidade de Vitória, Espírito Santo, Brasil, relatando o aparecimento de lesões verrucosas de crescimento progressivo na genitália externa por quatro meses. A paciente foi submetida à exérese cirúrgica e a confirmação diagnóstica de condiloma gigante foi obtida através da histopatologia. Ela foi medicada com imiquimode creme a 5% em aplicações rotineiras por oito semanas consecutivas para evitar recorrências e foi também vacinada contra o HPV após o procedimento.
Exérese cirúrgica é o tratamento de escolha em lesões condilomatosas extensas para excluir malignidade. O uso de Imiquimode como terapia adjuvante para redução de recidivas mostrou-se adequado.
Giant condylomata acuminata, also known as Buschke-Lowenstein tumor, is a rare form of tumor of the anogenital condylomata acuminate1, which is a sexually transmitted infection (STI) caused by the human papillomavirus (HPV). Approximately 40 of known HPV have tropism for the anogenital site, and giant condylomata is associated with infection by HPV 6 and 112. It is characterized by an extensive exophytic benign warty lesion with the potential for malignancy and local aggressive behavior1. Several therapeutic possibilities have been reported for the management of the giant condylomata acuminata, with variable outcomes. Surgical local excision is the treatment of choice in most hospital services, alone or in association with other treatment options like radiation therapy, topical and intralesional chemotherapy, systemic interferon α-2b, carbon dioxide laser, and topical therapies including 5% imiquimod that can reduce recurrence, podophyllin and therapeutic vaccine, which is currently under research2. Although several warts are considered benign, a long-lasting genital lesion can turn malignant due to contact between the virus and the immunologic system. Thus, the time to remove the giant condylomata acuminata to prevent a carcinomatous transition needs to be prompt.
This study aimed to report a giant condylomata acuminata in an immunocompetent patient and to describe the therapeutic management.
A 21-year-old female patient, married for about six months, farmer, with incomplete high school, and no condom use in oral and vaginal sexual intercourse was referred to the Outpatient Clinic for Sexually Transmitted Infections and AIDS at a public hospital in the city of Vitória, Espírito Santo State, Brazil, reporting onset of progressive growth verrucous lesions on the external genitalia for four months. She was treated with benzathine penicillin and oral metronidazole previously and denied smoking, drinking, or drug use. The tumor was painful and bleeding due to secondary bacterial infection. Physical examination revealed bilateral coalescent verrucous lesion occupying the whole extension of labia majora and minora as well as perianal lesions clinically compatible with Buschke-Lowenstein giant genital condylomata (
Cervical examination was unchanged, and cervical and vaginal cytology, colposcopy, and otolaryngologic examination were unchanged; moreover, serological tests for HIV, viral hepatitis, and syphilis presented no abnormalities. The sexual partner underwent serological tests that were unchanged, and genital inspection did not present condylomata lesions. Hospitalization was indicated, and gentamicin was administered for two weeks. The patient underwent a surgical ablation, and giant condylomata diagnostic confirmation was obtained through histopathology, which showed hyperkeratosis and papillomatosis with multiple koilocytes, with fast mitotic activity and no cellular atypia, suggestive of HPV infection (
HPV 11 was identified by the PCR test. After surgery, in a 30-day follow-up consultation, she presented persistent perianal lesions (
The study project was submitted to the Ethical Committee for Research of the Federal University of Espírito Santo.
Giant condylomata acuminata is a very rare clinical condition1. Currently, surgery can be avoided in some patients due to developed topical therapeutic methods3. Conversely, surgical excision remains the standard therapy in cases of high-risk condylomata acuminata or if topical therapy appears unworkable due to the size of the affected lesion3,4. Here, a case of a rapid-growth HPV lesion in a female patient was reported, who was very embarrassed about her condition and lived in a difficult access region. The condition, HPV 11, was identified by PCR test, in concordance with literature reviews2,3. The patient was evaluated for STI and cervical cancer prevention due to its HPV association, as cytological screening to detect precursor lesions is still paramount in some Brazilian regions5. She underwent high-frequency surgical excision, which is indicated for extensive condylomata lesions due to its advantages in controlling hemostasis, resolution rates in 90% of cases, and recurrence of about 25%2,3,4. Moreover, surgical ablation is the first option to exclude malignancy and to avoid the development of giant condilomata4,6. Recurrences may occur in 25 to 66% of cases after surgical treatment, according to some authors3,7, which are avoided by use of imiquimod after surgery in regular applications for eight consecutive weeks as well as by HPV vaccination. HPV vaccines have been known for their protecting results on cervical cancer and genital warts, though the treatment outcome is still indefinite. Therapeutic vaccine for HPV aims to generate cell-mediated immunity and studies on the subject are in progress8,9. Currently, a prospective study suggested that HPV vaccines could be effective in the management of genital warts9.
Imiquimod, an immune response modulator, has also been used, in regular applications, as an alternative therapy in HPV lesions by inducing the production of interferon alfa and cytokines, enhancing the immune response against HPV infected cells3,10.
Therefore, the association of surgical techniques and topical 5% imiquimod therapy was successful in this case report, highlighting that the controlling needs to be individualized.
Surgery excision is the treatment of choice in extensive genital condylomata lesions and should be readily instituted to exclude malignancy. Imiquimod use as adjuvant therapy for reduced recurrence seems to be appropriate, as in the present case.
No specific funding was received for this study.
HELENA LUCIA BARROSO DOS REIS. Ambulatório de Ginecologia e Obstetrícia, Universidade Federal do Espírito Santo. Avenida Marechal Campos, 1468 - Maruípe, Vitória (ES), Brazil. CEP: 29043-260. E-mail: firstname.lastname@example.org